Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world phase 4 study of tenofovir alafenamide in chronic hepatitis B patients at high risk of osteopenia or osteoporosis in China
ChiCTR1900025439Phase 4Not yet recruiting
- Sponsor
- Second People's Hospital of Yunnan Province
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Second People's Hospital of Yunnan Province. Primary endpoint: Bone mineral density at 48 weeks. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR1900025439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025439.